Vaccine variety is the key to ending pandemics

Vaccine variety is the key to ending pandemics

Continue reading →

Drugs affordability vs R&D development

Drugs affordability vs R&D development

Continue reading →

Horseshoe crab blood is key to making a Covid-19 vaccine – but the ecosystem may suffer

Horseshoe crab blood is key to making a Covid-19 vaccine – but the ecosystem may suffer

In 2016 a synthetic alternative (rFC) to horseshoe crab blood, used in bacterial infection detection for injectable procedures, was licensed. And yet horseshoe crabs are both threatened with extinction and in line for preservation due to Covid-19 and its...

Continue reading →

How will the rise of biosimilars impact biologics

How will the rise of biosimilars impact biologics

● Once patents expire for biologic medicines, a market opportunity opens up for biosimilars, a cheaper alternative. Biosimilars were mainly brought in to thwart the monopoly power of biologics in the pharmaceutical industry. ● Biosimilars are expected to increase at...

Continue reading →

Hospital margins are down – is selling your health data a solution

Hospital margins are down – is selling your health data a solution

A framework allowing a more sensible approach to health data collection In our previous blog we outlined the pressure on hospital margins and the entire hospital business model as a direct result of Covid-19. One solution is the sale by...

Continue reading →

Is producing a non-profit Covid-19 vaccine a smart decision for AstraZeneca and the industry

Is producing a non-profit Covid-19 vaccine a smart decision for AstraZeneca and the industry

AZN's market-cap breached the £100bn break-out line thanks to the Covid-crisis, the British pharma giant promised that during the pandemic it won’t make profit on the vaccine, but maybe it should.         AZN.L relative 12m share price performance (lighter line) vs....

Continue reading →

Why are drug prices rising faster than inflation?

Why are drug prices rising faster than inflation?

Drug makers typically raise prices at the beginning of the year and this year is no different. Prices on 457 brand name drugs are due to increase this year by an average of 5.1%. (GoodRx). About 102 drug manufacturers,...

Continue reading →